Purilogics

Executive Summary

Purilogics, a brand under Donaldson Life Science, specializes in membrane chromatography technology for downstream bioprocessing, offering the Purexa™ membrane platform. This innovative solution addresses key bottlenecks in biologics purification by providing rapid cycle times, consistent performance, and scalability from lab to commercial scale. Unlike traditional resin-based columns, Purexa membranes enable flow-through or bind-and-elute purification with high productivity and low buffer consumption, reducing costs and processing times. Founded in 2013 and headquartered in Greenville, South Carolina, Purilogics targets the growing demand for efficient and cost-effective purification methods in monoclonal antibodies, gene therapies, and vaccines. As part of Donaldson’s filtration expertise, the company integrates robust engineering with bioprocess-specific design, positioning itself as a competitive alternative to legacy chromatography players. With the bioprocessing market expanding rapidly due to increased biologics production and need for continuous manufacturing, Purilogics is well-poised to capture market share through its differentiated technology.

Upcoming Catalysts (preview)

• Q3 2026Launch of Commercial-Scale Purexa GMP Membrane Units75% success
• H2 2026Strategic Partnership with Major CDMO for Platform Adoption60% success
• Q4 2026FDA Master File Submission for Purexa Raw Materials80% success